Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

	Arthritis
	The latest arthritis news from News Medical

	Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.

	Forever chemicals cross placenta and breast milk affecting babies’ immunity New research reveals that tiny amounts of PFAS-widely known as "forever chemicals"-cross the placenta and breast milk to alter infants' developing immune systems, potentially leaving lasting imprints on their ability to fight disease.

			How targeted therapies are reshaping autoimmune disease treatment Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.

			New approach doubles chemotherapy effectiveness by targeting cancer cell memory In a wholly new approach to cancer treatment, Northwestern University biomedical engineers have doubled the effectiveness of chemotherapy in animal experiments.

			Study reveals key role of Egr-1 in controlling autoimmune diseases Autoimmune diseases, like multiple sclerosis result when the body's immune system starts to attack its own cells. Regulatory T cells, a subtype of T cells play a critical role in suppressing these attacks.

	Novel DNA plasmid therapy shows high success rate in treating chronic pain in dogs Elenagen™, a novel DNA plasmid therapy that previously demonstrated high clinical benefit and low toxicity in cancer patients, has now shown significant promise in alleviating chronic pain demonstrating a 90% success rate.

	The role of cytokines in autoimmune disease progression and therapy Explore how cytokines contribute to autoimmune disease development and discover emerging therapies.

	Hispanic people more likely to develop peripheral neuropathy than white adults Hispanic people have an increased risk of peripheral neuropathy compared to white people that cannot be explained by many health, lifestyle and social risk factors, according to a study published July 16, 2025, in Neurology, the medical journal of the American Academy of Neurology.

	Safeguarding your spinal health In this article, we take a closer look at targeted therapies for spinal and bone conditions.

	Antibody-drug conjugates beyond oncology Learn how antibody-drug conjugates are advancing therapies for non-cancer conditions, unlocking new possibilities in precision medicine.

	Biological drug mechanisms in autoimmune diseases Understand the mechanisms behind biological drugs and how they help manage autoimmune conditions.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2025